KR20230173129A - 화합물 smtp-7을 포함하는 약제학적 조성물 - Google Patents
화합물 smtp-7을 포함하는 약제학적 조성물 Download PDFInfo
- Publication number
- KR20230173129A KR20230173129A KR1020237038571A KR20237038571A KR20230173129A KR 20230173129 A KR20230173129 A KR 20230173129A KR 1020237038571 A KR1020237038571 A KR 1020237038571A KR 20237038571 A KR20237038571 A KR 20237038571A KR 20230173129 A KR20230173129 A KR 20230173129A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- additive
- smtp
- composition according
- polyoxyethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021070892 | 2021-04-20 | ||
| JPJP-P-2021-070892 | 2021-04-20 | ||
| PCT/US2022/025462 WO2022226013A1 (en) | 2021-04-20 | 2022-04-20 | Pharmaceutical composition comprising the compound smtp-7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230173129A true KR20230173129A (ko) | 2023-12-26 |
Family
ID=81648879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237038571A Pending KR20230173129A (ko) | 2021-04-20 | 2022-04-20 | 화합물 smtp-7을 포함하는 약제학적 조성물 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240238252A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4326258A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024525239A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230173129A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117279634A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022262593A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023021803A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3214630A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022226013A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240238248A1 (en) * | 2021-05-10 | 2024-07-18 | Ji Xing Pharmaceuticals Hong Kong Limited | Pharmaceutical composition for use in treating cerebral infarction |
| WO2026092761A1 (zh) * | 2024-11-04 | 2026-05-07 | 江苏恒瑞医药股份有限公司 | 包含smtp衍生物的药物组合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004224737A (ja) | 2003-01-23 | 2004-08-12 | Ttc:Kk | 新規トリプレニルフェノール化合物 |
| JP4313049B2 (ja) | 2003-01-23 | 2009-08-12 | 株式会社ティーティーシー | 血管新生関連疾患の予防又は治療用医薬組成物 |
| JPWO2007040082A1 (ja) | 2005-10-06 | 2009-04-16 | 国立大学法人東京農工大学 | 腎炎治療又は予防用医薬組成物及びその製造方法 |
| KR20080112184A (ko) | 2006-03-27 | 2008-12-24 | 노우코우다이 티엘오 가부시키가이샤 | 트리프레닐페놀화합물과 트리프레닐페놀화합물의 제조방법,및 혈전용해촉진제 |
| JP2008201688A (ja) * | 2007-02-16 | 2008-09-04 | Tms Co Ltd | 皮膚老化防止剤、化粧料及び皮膚外用剤 |
| JP5605659B2 (ja) * | 2009-07-06 | 2014-10-15 | 国立大学法人東京農工大学 | 細胞保護剤 |
| WO2011125930A1 (ja) | 2010-04-02 | 2011-10-13 | 日本製薬株式会社 | 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤 |
| JP7381035B2 (ja) * | 2018-11-02 | 2023-11-15 | 学校法人昭和大学 | Smtp一群又はsmtp-7の製造中間体及びその化学的製造方法 |
| US20240238248A1 (en) * | 2021-05-10 | 2024-07-18 | Ji Xing Pharmaceuticals Hong Kong Limited | Pharmaceutical composition for use in treating cerebral infarction |
-
2022
- 2022-04-20 WO PCT/US2022/025462 patent/WO2022226013A1/en not_active Ceased
- 2022-04-20 BR BR112023021803A patent/BR112023021803A2/pt unknown
- 2022-04-20 JP JP2023563075A patent/JP2024525239A/ja active Pending
- 2022-04-20 AU AU2022262593A patent/AU2022262593A1/en active Pending
- 2022-04-20 CN CN202280033984.6A patent/CN117279634A/zh active Pending
- 2022-04-20 CA CA3214630A patent/CA3214630A1/en active Pending
- 2022-04-20 US US18/287,489 patent/US20240238252A1/en active Pending
- 2022-04-20 KR KR1020237038571A patent/KR20230173129A/ko active Pending
- 2022-04-20 EP EP22723282.4A patent/EP4326258A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022226013A1 (en) | 2022-10-27 |
| JP2024525239A (ja) | 2024-07-11 |
| CA3214630A1 (en) | 2022-10-27 |
| CN117279634A (zh) | 2023-12-22 |
| AU2022262593A1 (en) | 2023-11-02 |
| BR112023021803A2 (pt) | 2024-01-23 |
| US20240238252A1 (en) | 2024-07-18 |
| EP4326258A1 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7042531B2 (ja) | デオキシコール酸を含む医薬組成物 | |
| US9107925B2 (en) | Sodium channel blocker for treatment of loss of superficial sensitivity | |
| JP5522877B2 (ja) | モキシフロキサシン/塩化ナトリウム製剤 | |
| JP2010523696A (ja) | 脳腫瘍を治療する方法 | |
| KR20200018485A (ko) | 우울 장애들의 치료 | |
| CN104918619A (zh) | 稳定的肠胃外dnj组合物 | |
| KR102656841B1 (ko) | 레파뮬린의 주사가능한 약제학적 제형 | |
| US20240238252A1 (en) | Pharmaceutical composition comprising the compound smtp-7 | |
| EP4223313A1 (en) | Pharmaceutical composition comprising acid-base neutralization combination and application thereof | |
| CN120265283A (zh) | (-)-表没食子儿茶素没食子酸酯类化合物的应用 | |
| EP4495122A1 (en) | Artemisinin derivatives, preparation method therefor, and uses thereof | |
| JP7857158B2 (ja) | 透析患者に適用される注射用医薬組成物 | |
| US20240238248A1 (en) | Pharmaceutical composition for use in treating cerebral infarction | |
| EP1941880B1 (en) | Lotion preparation containing pyridonecarboxylic acid derivative | |
| US7262317B2 (en) | Freeze-dried preparation of n[o-(p-pivaloyloxybenzenasulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and process for producing same | |
| WO2004098614A1 (ja) | メチルコバラミン含有凍結乾燥製剤及びその製造方法 | |
| HK40105250A (en) | Pharmaceutical composition comprising the compound smtp-7 | |
| US20240024299A1 (en) | Use of drugs that stiffen mature gametocytes for blocking transmission of plasmodium parasites | |
| KR20120089444A (ko) | 정맥내 이부프로펜에 의한 위독한 환자의 치료방법 | |
| KR20080096829A (ko) | 정맥내 항바이러스 치료 | |
| US20240415815A1 (en) | Ionic-liquid-based formulations for the prevention or treatment of neurological diseases | |
| WO2026013454A1 (en) | Multi-dose pen of tirzepatide | |
| EP4415720A1 (en) | Novel parenteral composition comprising linagliptin or its salts | |
| WO2020188457A1 (en) | Solutions for oral dosage | |
| HK1179530B (en) | Treatment of loss of sense of touch with saxitoxin derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |